Evaluating utility and feasibility of mismatch repair testing of colorectal cancer patients in a low-middle-income country.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 06 2022
29 06 2022
Historique:
received:
29
12
2021
accepted:
09
06
2022
entrez:
29
6
2022
pubmed:
30
6
2022
medline:
2
7
2022
Statut:
epublish
Résumé
Molecular pathology services for colorectal cancer (CRC) in Sudan represent a significant unmet clinical need. In a retrospective cohort study involving 50 patients diagnosed with CRC at three major medical settings in Sudan, we aimed to outline the introduction of a molecular genetic service for CRC in Sudan, and to explore the CRC molecular features and their relationship to patient survival and clinicopathological characteristics. Mismatch repair (MMR) and BRAF (V600E) mutation status were determined by immunohistochemistry. A mismatch repair deficient (dMMR) subtype was demonstrated in 16% of cases, and a presumptive Lynch Syndrome (LS) diagnosis was made in up to 14% of patients. dMMR CRC in Sudan is characterized by younger age at diagnosis and a higher incidence of right-sided tumours. We report a high mortality in Sudanese CRC patients, which correlates with advanced disease stage, and MMR status. Routine MMR immunohistochemistry (with sequential BRAF mutation analysis) is a feasible CRC prognostic and predictive molecular biomarker, as well as a screening tool for LS in low-middle-income countries (LMICs).
Identifiants
pubmed: 35768447
doi: 10.1038/s41598-022-14644-6
pii: 10.1038/s41598-022-14644-6
pmc: PMC9243080
doi:
Substances chimiques
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10998Informations de copyright
© 2022. The Author(s).
Références
BMJ Glob Health. 2019 Aug 21;4(4):e001723
pubmed: 31543996
Front Oncol. 2018 Sep 04;8:346
pubmed: 30234014
J Clin Oncol. 2010 Jul 10;28(20):3219-26
pubmed: 20498393
Sci Rep. 2019 Oct 21;9(1):15019
pubmed: 31636305
Clin Gastroenterol Hepatol. 2010 Jun;8(6):523-9
pubmed: 20303416
Lancet. 2018 May 12;391(10133):1939-1952
pubmed: 29550027
Public Health Genomics. 2015;18(4):242-7
pubmed: 26138992
J Gastrointest Cancer. 2019 Sep;50(3):530-536
pubmed: 29850986
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Womens Health (Lond). 2016 Jan;12(1):147-56
pubmed: 26757491
Nat Genet. 2006 Jul;38(7):787-93
pubmed: 16804544
Am J Clin Pathol. 2013 Aug;140(2):177-83
pubmed: 23897252
Cancer Causes Control. 2009 Nov;20(9):1763-8
pubmed: 19669908
Lancet Gastroenterol Hepatol. 2017 May;2(5):377-383
pubmed: 28397702
Virchows Arch. 2021 May;478(5):851-863
pubmed: 33170334
Am J Surg Pathol. 2016 Apr;40(4):e17-34
pubmed: 26974895
Cancers (Basel). 2020 Aug 20;12(9):
pubmed: 32825275
Virchows Arch. 2016 Aug;469(2):125-34
pubmed: 27325016
Nat Rev Clin Oncol. 2020 Jan;17(1):11-32
pubmed: 31289352
Anticancer Res. 2017 May;37(5):2649-2654
pubmed: 28476840
IARC Sci Publ. 2011;(162):257-91
pubmed: 21675431
J Clin Pathol. 2018 Jul;71(7):631-636
pubmed: 29419411
PLoS One. 2017 Mar 2;12(3):e0172799
pubmed: 28253296
Crit Rev Oncol Hematol. 2017 Aug;116:38-57
pubmed: 28693799
Cancer. 2018 Jul 1;124(13):2785-2800
pubmed: 29786848
Lancet. 2018 May 12;391(10133):1927-1938
pubmed: 29550029
Clin Cancer Res. 2003 Mar;9(3):1112-7
pubmed: 12631615
J Clin Oncol. 2016 Sep 1;34(25):3039-46
pubmed: 27432916
Exp Mol Pathol. 2020 Oct;116:104519
pubmed: 32822722
PLoS One. 2019 Oct 24;14(10):e0224023
pubmed: 31647837
Front Genet. 2019 Oct 08;10:944
pubmed: 31649727
Clin Cancer Res. 2018 Feb 15;24(4):794-806
pubmed: 29242316
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Afr Health Sci. 2015 Jun;15(2):576-80
pubmed: 26124805